ライフサイエンスコーパス: urokinase receptor

1 asminogen activator inhibitor type-1 and the urokinase receptor.

2 A-dependent ERK signaling via an alternative urokinase receptor.

3 s were confirmed on cells expressing variant urokinase receptor.

4 occur through interactions with endothelial urokinase receptors.

5 Since the binding of urokinase to urokinase receptors activates signaling responses and ma

6 Because urokinase receptor.alpha5beta1 complexes bind in the fib

7 ed growth factor, matrix metalloproteinases, urokinase receptor and varied small-molecule tyrosine ki

8 as decreased expression of c-met, urokinase, urokinase receptor, and TGF-beta1.

9 n of metastasis, these findings suggest that urokinase receptor antagonists may be useful therapeutic

10 ands and a basis for the design of urokinase-urokinase receptor antagonists.

11 portion of human IgG as high-affinity murine urokinase receptor antagonists.

12 Urokinase receptors bind urokinase and a set of beta1 in

13 We found that uPAR ligation with the urokinase receptor binding domain (amino-terminal fragme

14 Thus urokinase receptor binding to alpha5beta1 is required fo

15 he crystal structure at 1.9 angstroms of the urokinase receptor complexed with the urokinase amino-te

16 Although Mrc2 associates with the urokinase receptor, differences in renal urokinase activ

17 , lymphocyte antigen-6/plasminogen activator urokinase receptor domain containing protein 6B (LYPD6B)

18 Lymphocyte antigen-plasminogen activator urokinase receptor domain-containing protein 6B (Lypd6b)

19 ocyte antigen, PLAUR (plasminogen activator, urokinase receptor) domain-containing (LYPD)-6B on alpha

20 xperiments using nuclear extract from a high urokinase receptor-expressing cell line (RKO) indicated

21 urokinase receptor promoter activity in low urokinase receptor-expressing GEO cells was increased by

22 ine if a constitutively active Src regulates urokinase receptor expression and 2) to identify require

23 elements and trans-acting factors activating urokinase receptor expression through a footprinted (-14

24 yristate 13-acetate treatment, which induces urokinase receptor expression, increased complex formati

25 eceptor promoter (-152/-135) in constitutive urokinase receptor expression, we determined its role fo

26 The three domains of urokinase receptor form a concave shape with a central c

27 vely active Src protein manifested increased urokinase receptor gene expression and Src activity.

28 These data suggest that urokinase receptor gene expression is regulated by Src p

29 grins, but it remains unclear to what degree urokinase receptor/integrin binding is important to beta

30 The urokinase receptor is composed of three homologous domai

31 state 13-acetate-inducible expression of the urokinase receptor is mediated partly through trans-acti

32 Up-regulation of urokinase receptors is common during tumor progression a

33 PLAP and the carboxy-terminal portion of the urokinase receptor (MP/uPAR) into which various amino ac

34 ntified that zymogen FXII interacts with the urokinase receptor on neutrophils and upregulates neutro

35 The urokinase receptor overexpressed in invasive cancers pro

36 C receptor), and fibrinolytic (urokinase and urokinase receptor) pathways were significantly reduced

37 the GEO cells which have approximately 10(4) urokinase receptors per cell.

38 issue factor (F3; TF), urokinase (PLAU), and urokinase receptor (PLAUR) (herein, "coagulopathy-relate

39 ssense variant in the plasminogen activator, urokinase receptor (PLAUR) gene (rs4760), confirmed expe

40 ceptor B2 (EPHB2), and plasminogen activator urokinase receptor (PLAUR)] that were decreased more tha

41 ecently implicated an upstream region of the urokinase receptor promoter (-152/-135) in constitutive

42 Conversely, urokinase receptor promoter activity in low urokinase re

43 r of activator protein-2 function diminished urokinase receptor promoter activity, protein, and lamin

44 tor protein 2alpha-related factor diminished urokinase receptor promoter activity.

45 a-related factor and Sp1/Sp3 binding reduced urokinase receptor promoter stimulation by this agent.

46 Finally, endogenous urokinase receptor protein amounts in 10 colon cancers a

47 vasiveness and because both Src activity and urokinase receptor protein are elevated in invasive colo

48 ants with a Src-inhibitor (PD173955) reduced urokinase receptor protein levels and laminin degradatio

49 Knockdown of urokinase receptors resulted in markedly reduced fibrone

50 Elevation in soluble urokinase receptor (suPAR) and proteinuria are common si

51 Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal mo

52 Recently, serum soluble urokinase receptor (suPAR) has been proposed as a cause

53 Soluble urokinase receptor (suPAR) is a circulatory molecule tha

54 Here we report that serum soluble urokinase receptor (suPAR) is elevated in two-thirds of

55 Serum soluble urokinase receptor (suPAR) levels strongly predict incid

56 The urokinase receptor system is a key regulator of the inte

57 provides insight into the flexibility of the urokinase receptor that enables its interaction with a w

58 inogen (Pg(-)(/-)), urokinase (u-PA(-)(/-)), urokinase receptor (u-PAR(-)(/-)), or tissue plasminogen

59 The urokinase receptor (u-PAR) which is largely regulated at

60 Expression of the urokinase receptor uPAR is essential to the development

61 Hypoxia induces expression of the urokinase receptor (uPAR) and activates uPAR-dependent c

62 uantitative increases in urokinase PA (uPA), urokinase receptor (uPAR) and plasminogen activator inhi

63 s significantly increased levels of cellular urokinase receptor (uPAR) and release increased amounts

64 The nonintegrin urokinase receptor (uPAR) associates with and stabilizes

65 The urokinase receptor (uPAR) attenuates myofibroblast recru

66 Although the urokinase receptor (uPAR) binds to vitronectin (VN) and

67 The urokinase receptor (uPAR) binds urokinase-type plasminog

68 The urokinase receptor (uPAR) coordinates plasmin-mediated c

69 e that in EGFRvIII-expressing GBM cells, the urokinase receptor (uPAR) functions as a major activator

70 etermine the role of urokinase (uPA) and the urokinase receptor (uPAR) in retinal angiogenesis, and w

71 The urokinase receptor (uPAR) is a cell-signaling receptor k

72 The urokinase receptor (uPAR) is a founding member of a smal

73 The urokinase receptor (uPAR) is a glycosylphosphatidylinosi

74 Given that the urokinase receptor (uPAR) is known to play a role in cel

75 The urokinase receptor (uPAR) is linked to cellular migratio

76 Neither the urokinase receptor (uPAR) nor the low-density lipoprotei

77 The urokinase receptor (uPAR) plays an important role in reg

78 The urokinase receptor (uPAR) promotes metastasis of human m

79 Here we show that induction of urokinase receptor (uPAR) signaling in podocytes leads t

80 These cells overexpress urokinase receptor (uPAR) which, by activating alpha5bet

81 here we report the sequestration behavior of urokinase receptor (uPAR), a glycosylphosphatidylinosito

82 CDC91L1 also resulted in upregulation of the urokinase receptor (uPAR), a GPI-anchored protein, and i

83 , through unknown receptors, overexpress the urokinase receptor (uPAR), a key mediator of the plasmin

84 A second integrin ligand, the urokinase receptor (uPAR), associates with alpha3beta1 v

85 One such protein, the glycolipid-anchored urokinase receptor (uPAR), associates with and modifies

86 The urokinase receptor (uPAR), expressed on the surface of m

87 urokinase-type plasminogen activator (uPA), urokinase receptor (uPAR), tissue-type plasminogen activ

88 ted on the surface of many cell types, where urokinase receptor (uPAR)-bound urokinase (uPA) activate

89 nse to EGF only when these cells express the urokinase receptor (uPAR).

90 inogen activator inhibitor-1 (PAI-1) and the urokinase receptor (uPAR).

91 ator inhibitor complexes (uPA:PAI-1) and the urokinase receptor (uPAR).

92 ly on endothelial cells to domain 2/3 of the urokinase receptor (uPAR).

93 lls, which express both LRP/alpha2MR and the urokinase receptor (uPAR).

94 eukocyte integrin Mac-1 (CD11b/CD18) and the urokinase receptor (uPAR, CD87) mediate complementary fu

95 ase-type plasminogen activator (uPA) and the urokinase receptor (uPAR, CD87).

96 R4 physically and functionally interact with urokinase receptors (uPAR) on neutrophil plasma membrane

97 beta2 integrins for substrate attachment and urokinase receptors (uPAR) to focus pericellular proteol

98 Urokinase receptors (uPAR; CD87) from complexes with com

99 Leukocytes use urokinase receptors (uPAR; CD87) in adhesion, migration,

100 Leukocytes utilize urokinase receptors (uPAR; CD87) in adhesion, migration,

101 hly colocalized on the cell surface with the urokinase receptor, uPAR.

102 The urokinase receptor urokinase-type plasminogen activator

103 Binding to the urokinase receptor was completely abolished while PAI-1

104 utagenesis, single amino acid mutants of the urokinase receptor were identified that fail to associat

105 tions on beta1 integrin function, endogenous urokinase receptors were first stably silenced in tumor

106 ffract in the co-crystal, and a site for the urokinase receptor, which overlaps with the PAI-1-bindin